BR112014031471A2 - composição líquida, uso da composição líquida, dispersão sólida, processo para produzir a dispersão sólida e processo para revestir uma forma de dosagem - Google Patents

composição líquida, uso da composição líquida, dispersão sólida, processo para produzir a dispersão sólida e processo para revestir uma forma de dosagem

Info

Publication number
BR112014031471A2
BR112014031471A2 BR112014031471A BR112014031471A BR112014031471A2 BR 112014031471 A2 BR112014031471 A2 BR 112014031471A2 BR 112014031471 A BR112014031471 A BR 112014031471A BR 112014031471 A BR112014031471 A BR 112014031471A BR 112014031471 A2 BR112014031471 A2 BR 112014031471A2
Authority
BR
Brazil
Prior art keywords
liquid composition
solid dispersion
coating
dosage form
cellulose ether
Prior art date
Application number
BR112014031471A
Other languages
English (en)
Other versions
BR112014031471B1 (pt
Inventor
j hall Mark
Knarr Matthias
Brackhagen Meinolf
S Grasman Nicholas
L Schmitt Robert
J Guillaudeu Steven
Original Assignee
Dow Global Technologies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Global Technologies Llc filed Critical Dow Global Technologies Llc
Publication of BR112014031471A2 publication Critical patent/BR112014031471A2/pt
Publication of BR112014031471B1 publication Critical patent/BR112014031471B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/08—Cellulose derivatives
    • C08L1/26—Cellulose ethers
    • C08L1/28—Alkyl ethers
    • C08L1/284—Alkyl ethers with hydroxylated hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

resumo “composição líquida, uso da composição líquida, dispersão sólida, processo para produzir a dispersão sólida e processo para revestir uma forma de dosagem” uma composição líquida que compreende um diluente líquido orgânico e pelo menos um éter de celulose não iônico tendo uma viscosidade de até 2,33 mpa*s, medida como uma solução a 2% em peso em água a 20°c, é estável durante um extenso período de tempo. a composição líquida é útil para preparar uma dispersão sólida compreendendo pelo menos um ingrediente ativo em pelo menos um éter de celulose por secagem por aspersão. alternativamente, pode-se produzir uma dispersão sólida misturando e extrudando pelo menos um ingrediente ativo, pelo menos um éter de celulose tendo uma viscosidade de até 2,33 mpa*s e opcionalmente, um ou mais adjuvantes. 1/1
BR112014031471-3A 2012-07-17 2013-07-12 composição líquida, uso da composição líquida, dispersão sólida, processo para produzir a dispersão sólida e processo para revestir uma forma de dosagem BR112014031471B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261672411P 2012-07-17 2012-07-17
US61/672,411 2012-07-17
PCT/US2013/050216 WO2014014753A1 (en) 2012-07-17 2013-07-12 Composition comprising an organic liquid diluent and a cellulose ether of very low viscosity

Publications (2)

Publication Number Publication Date
BR112014031471A2 true BR112014031471A2 (pt) 2017-06-27
BR112014031471B1 BR112014031471B1 (pt) 2020-12-01

Family

ID=48875198

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014031471-3A BR112014031471B1 (pt) 2012-07-17 2013-07-12 composição líquida, uso da composição líquida, dispersão sólida, processo para produzir a dispersão sólida e processo para revestir uma forma de dosagem

Country Status (7)

Country Link
US (3) US20150209436A1 (pt)
EP (1) EP2875072B1 (pt)
JP (2) JP2015524395A (pt)
KR (1) KR102220604B1 (pt)
CN (1) CN104603194B (pt)
BR (1) BR112014031471B1 (pt)
WO (1) WO2014014753A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3049061B1 (en) 2013-09-25 2018-06-20 Dow Global Technologies LLC Composition comprising an organic liquid diluent and a specific hydroxyalkyl methylcellulose
WO2016200673A1 (en) * 2015-06-09 2016-12-15 Dow Global Technologies Llc Support materials for 3d printing
US20200283655A1 (en) * 2019-02-01 2020-09-10 SE Tylose USA, Inc. Coating formulation using low-substituted cellulose ether and its preparation

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2748111A (en) * 1956-05-29 Preparation of cellulose ether
US3477864A (en) * 1965-05-07 1969-11-11 Sumitomo Chemical Co Process for coating pharmaceutical preparations with a hydroxy propyl methyl cellulose-sealing agent moisture-preventing film
GB1357737A (en) * 1970-10-09 1974-06-26 Arpic Sa Sustained release pharmaceutical compositions
US3769247A (en) * 1972-04-10 1973-10-30 Dow Chemical Co Cellulose ether thickener for latex paint
US4061859A (en) 1976-06-14 1977-12-06 The Dow Chemical Company Viscosity reduction of cellulose derivatives
US4302440B1 (en) * 1980-07-31 1986-08-05 Easily-swallowed, powder-free and gastric-disintegrable aspirin tablet thinly-coated with hydroxypropyl methylcellulose and aqueous spray-coating preparation thereof
JPH089680B2 (ja) * 1990-07-02 1996-01-31 アクアロン・カンパニー 高固形分、低粘度の多糖組成物
US5054511A (en) 1990-09-11 1991-10-08 Tuan C T Tire valve having an automatic pressure release device
EP0872233A1 (en) 1997-04-14 1998-10-21 Janssen Pharmaceutica N.V. Antiretroviral compositions with improved bioavailability
KR20010097244A (ko) * 2000-04-21 2001-11-08 유충식 위산도 비의존성 고용해도를 갖는 이트라코나졸 함유약학적 조성물 및 그 제조방법
JP4490097B2 (ja) * 2001-09-04 2010-06-23 ダウ グローバル テクノロジーズ インコーポレイティド 固体粒子を被覆する方法
CA2468040A1 (en) * 2001-12-07 2003-06-12 Janssen Pharmaceutica N.V. Preparation of cis-fused 3,3a,8,12b-tetrahydro-2h-dibenzo[3,4:6,7]cyclohepta[1,2-b]furan derivatives
AU2002217373A1 (en) * 2002-01-03 2003-07-15 Lek Pharmaceutical And Chemical Company D.D. Controlled release pharmaceutical formulation containing venlafaxine
WO2005118649A1 (en) 2004-05-26 2005-12-15 Dow Global Technologies Inc. Production of low molecular weight ethylcellulose
JP2008501009A (ja) 2004-05-28 2008-01-17 ファイザー・プロダクツ・インク 性能を高めた医薬組成物
JP2009504590A (ja) * 2005-08-08 2009-02-05 アボット ゲーエムベーハー ウント コンパニー カーゲー 改善された生物学的利用能をもつ剤型
EP2032608B1 (en) 2006-06-14 2011-08-10 Dow Global Technologies LLC Process for reducing the average molecular weight of cellulose ethers
US8372836B2 (en) 2006-10-17 2013-02-12 Bend Research, Inc. Spray dried formulation
US20080260837A1 (en) * 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
US8920553B2 (en) * 2007-11-09 2014-12-30 Dow Global Technologies Llc Cellulose ether coating compositions and method
MX2010004931A (es) * 2007-11-09 2010-06-11 Union Carbide Chem Plastic Metodo para preparar eter de celulosa de muy baja viscosidad y producto.
WO2012074042A1 (ja) * 2010-12-03 2012-06-07 日本曹達株式会社 ヒドロキシアルキルセルロース
JP5717424B2 (ja) * 2010-12-03 2015-05-13 学校法人神戸学院 コーティング粒子
PT2508207E (pt) * 2011-03-31 2013-07-22 Bioalliance Pharma Nanopartículas carregadas com um medicamento antitumoral quimioterapêutico
WO2015003140A1 (en) * 2013-07-03 2015-01-08 Wayne State University Method of making water soluble injectable calcium polyphosphate gels
JP7469879B2 (ja) * 2016-07-27 2024-04-17 コリウム， エルエルシー 経口送達と生物学的に同等である薬物動態を有する経皮送達システム

Also Published As

Publication number Publication date
BR112014031471B1 (pt) 2020-12-01
US20170028069A1 (en) 2017-02-02
CN104603194B (zh) 2017-11-24
JP2015524395A (ja) 2015-08-24
KR20150031300A (ko) 2015-03-23
US10272156B2 (en) 2019-04-30
WO2014014753A1 (en) 2014-01-23
CN104603194A (zh) 2015-05-06
EP2875072A1 (en) 2015-05-27
US11000594B2 (en) 2021-05-11
JP2016193908A (ja) 2016-11-17
JP6231613B2 (ja) 2017-11-15
KR102220604B1 (ko) 2021-03-02
US20150209436A1 (en) 2015-07-30
EP2875072B1 (en) 2017-03-15
US20190209693A1 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
BR112014029754B1 (pt) soluções de tensoativos que contêm n-metil-noleilglucaminas e n-metil-n-c12-c14 acilglucaminas e seu uso, processo para produzir composições cosméticas e composição
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
BR112015019657A2 (pt) composições tópicas e métodos de uso das mesmas
BR112018011688A2 (pt) composições de emulsão inversa
BR112015032340A2 (pt) composições e artigos para cuidados pessoais
BRPI0910182B8 (pt) composto de fórmula (i), composição farmacêutica e uso de um composto
UY31831A (es) Derivados de indazoles sustituidos con fenilo o piridinilo
BR112014000382A2 (pt) uso de microemulsões em composições cosméticas de limpeza
BR112016013195A2 (pt) Composições para a higiene bucal compreendendo carbonato de cálcio e uma argila
BR112014026307A2 (pt) preparação injetável
CO6420342A2 (es) Derivados de pirazol usados como antagonistas del receptor ccr4
BR112016013194A2 (pt) Composições de higiene oral compreendendo carbonato de cálcio e sílica
BR112014032017A2 (pt) dispersão sólida, dispersão sólida extrudada e processo para produzir uma dispersão sólida
BR112015005590A2 (pt) composição para tratamento de tecidos
BR112015015846A2 (pt) éter de celulose esterificado, composição, dispersão sólida, forma de dosagem, invólucro de cápsula e processo para produzir um éter de celulose esterificado
CO6351723A2 (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
BR112014004362A2 (pt) composição de revestimento, processo para preparar uma composição de revestimento, forma de dosagem e processo para revestir uma forma de dosagem
EA201691019A1 (ru) Композиции гиалуроновой кислоты, включающие мепивакаин
BR112015008601A2 (pt) argamassa
BR112012017994A2 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
BR112017004221A2 (pt) composição de abrilhantador sólido que compreende ácido poliacrílico
BR112014002940A2 (pt) uso e composição agroquímica de dibutilamidas de ácido carboxílico
BR112015032697A2 (pt) composição detergente líquida
BR112015021940A2 (pt) composição agrícola que compreende pelo menos uma substância química agrícola e pelo menos um éter de celulose; método de redução do desvio de pulverização durante a pulverização de uma solução aquosa; e método de aumento da resistência à lavagem pela chuva de uma solução aquosa pulverizada sobre uma superfície
AR088963A1 (es) Complejo obtenido a partir de mezclas de acido hialuronico o una sal del mismo y sulfato de condroitina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/07/2013, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: THE DOW CHEMICAL COMPANY (US)

B25A Requested transfer of rights approved

Owner name: DDP SPECIALTY ELECTRONIC MATERIALS US, INC. (US)

B25D Requested change of name of applicant approved

Owner name: DDP SPECIALTY ELECTRONIC MATERIALS US, LLC (US)

B25A Requested transfer of rights approved

Owner name: NUTRITION AND BIOSCIENCES USA 1, LLC (US)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 11A ANUIDADE.